Skip to main content
Erschienen in: American Journal of Clinical Dermatology 3/2023

25.01.2023 | Review Article

Muir–Torre Syndrome: A Cutaneous Finding Amidst Broader Malignancies

verfasst von: Rohan R. Shah, Priscilla Allman, Robert A. Schwartz

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Muir–Torre syndrome (MTS) is a rare autosomal dominant genetic condition resulting from microsatellite instability which is caused by mutations in DNA mismatch repair genes. This disorder predisposes individuals to skin tumors and visceral malignancies and may be precipitated in immunocompromised or transplant patients. MTS requires close cancer surveillance for the patient and family because of the tendency to develop aggressive internal malignancies and sebaceous carcinoma. Immunohistochemistry and or genetic testing can confirm the diagnosis of MTS. This review offers an update to the guidelines, diagnosis, and management of MTS while offering a unique perspective on an important but lesser-known syndrome.
Literatur
1.
Zurück zum Zitat Lee JB, Litzner BR, Vidal CI. Review of the current medical literature and assessment of current utilization patterns regarding mismatch repair protein immunohistochemistry in cutaneous Muir-Torre syndrome-associated neoplasms. J Cutan Pathol. 2017;44:931–7.CrossRefPubMed Lee JB, Litzner BR, Vidal CI. Review of the current medical literature and assessment of current utilization patterns regarding mismatch repair protein immunohistochemistry in cutaneous Muir-Torre syndrome-associated neoplasms. J Cutan Pathol. 2017;44:931–7.CrossRefPubMed
2.
Zurück zum Zitat Shalin SC, Lyle S, Calonje E, Lazar AJ. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. Histopathology. 2010;56:133–47.CrossRefPubMedPubMedCentral Shalin SC, Lyle S, Calonje E, Lazar AJ. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. Histopathology. 2010;56:133–47.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Coquillard C, Boustany A, DeCoster RC, Vasconez HC. Muir-Torre syndrome presenting as a sebaceous carcinoma of the Nasal Ala. Am Surg. 2019;85:e115–7.CrossRefPubMedPubMedCentral Coquillard C, Boustany A, DeCoster RC, Vasconez HC. Muir-Torre syndrome presenting as a sebaceous carcinoma of the Nasal Ala. Am Surg. 2019;85:e115–7.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Eiger-Moscovich M, Eagle RC Jr, Shields CL, Racher H, Lally SE, Silkiss RZ, et al. Muir-Torre syndrome associated periocular sebaceous neoplasms: screening patterns in the literature and in clinical practice. Ocular Oncol Pathol. 2020;6:226–37.CrossRef Eiger-Moscovich M, Eagle RC Jr, Shields CL, Racher H, Lally SE, Silkiss RZ, et al. Muir-Torre syndrome associated periocular sebaceous neoplasms: screening patterns in the literature and in clinical practice. Ocular Oncol Pathol. 2020;6:226–37.CrossRef
5.
Zurück zum Zitat Simic D, Dummer R, Freiberger SN, Ramelyte E, Barysch MJ. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome. Genes. 2021;12:781.CrossRefPubMedPubMedCentral Simic D, Dummer R, Freiberger SN, Ramelyte E, Barysch MJ. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome. Genes. 2021;12:781.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Rios CA, Villalón R, Muñoz J, Acuña M, Cifuentes L. Muir-Torre syndrome: case report and molecular characterization. Sao Paulo Med J Revista paulista de medicina. 2014;132:61–4.CrossRefPubMed Rios CA, Villalón R, Muñoz J, Acuña M, Cifuentes L. Muir-Torre syndrome: case report and molecular characterization. Sao Paulo Med J Revista paulista de medicina. 2014;132:61–4.CrossRefPubMed
7.
Zurück zum Zitat Wargo JJ, Plaza JA, Carr D. Sebaceous neoplasia leading to the diagnosis of Muir-Torre syndrome in an African American man. JAAD case reports. 2021;11:72–3.CrossRefPubMedPubMedCentral Wargo JJ, Plaza JA, Carr D. Sebaceous neoplasia leading to the diagnosis of Muir-Torre syndrome in an African American man. JAAD case reports. 2021;11:72–3.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat John AM, Schwartz RA. Muir-Torre syndrome (MTS): An update and approach to diagnosis and management. J Am Acad Dermatol. 2016;74:558–66.CrossRefPubMed John AM, Schwartz RA. Muir-Torre syndrome (MTS): An update and approach to diagnosis and management. J Am Acad Dermatol. 2016;74:558–66.CrossRefPubMed
9.
Zurück zum Zitat Roberts ME, Riegert-Johnson DL, Thomas BC, Rumilla KM, Thomas CS, Heckman MG, et al. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genet Med. 2014;16:711–6.CrossRefPubMed Roberts ME, Riegert-Johnson DL, Thomas BC, Rumilla KM, Thomas CS, Heckman MG, et al. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genet Med. 2014;16:711–6.CrossRefPubMed
10.
Zurück zum Zitat Grob A, Feser C, Grekin S. Muir-Torre syndrome: a case associated with an infrequent gene mutation. J Clin Aesthetic Dermatol. 2016;9:56–9. Grob A, Feser C, Grekin S. Muir-Torre syndrome: a case associated with an infrequent gene mutation. J Clin Aesthetic Dermatol. 2016;9:56–9.
11.
Zurück zum Zitat Singh RS, Grayson W, Redston M, Diwan AH, Warneke CL, McKee PH, Lev D, Lyle S, Calonje E, Lazar AJ. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol. 2008;32(6):936–42.CrossRefPubMed Singh RS, Grayson W, Redston M, Diwan AH, Warneke CL, McKee PH, Lev D, Lyle S, Calonje E, Lazar AJ. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol. 2008;32(6):936–42.CrossRefPubMed
13.
Zurück zum Zitat Marazza G, Masouyé I, Taylor S, Prins C, Gaudin T, Saurat JH, et al. An illustrative case of Muir-Torre syndrome: contribution of immunohistochemical analysis in identifying indicator sebaceous lesions. Arch Dermatol. 2006;142:1039–42.CrossRefPubMed Marazza G, Masouyé I, Taylor S, Prins C, Gaudin T, Saurat JH, et al. An illustrative case of Muir-Torre syndrome: contribution of immunohistochemical analysis in identifying indicator sebaceous lesions. Arch Dermatol. 2006;142:1039–42.CrossRefPubMed
14.
Zurück zum Zitat Chen Q, Wang M, Xu Z, Wang M, Jin S, Tian S, et al. Muir-Torre syndrome with a frame-shift mutation in the MSH2 gene: a rare case report and literature review. Int J Gynecol Pathol. 2020;39:136–40.CrossRefPubMed Chen Q, Wang M, Xu Z, Wang M, Jin S, Tian S, et al. Muir-Torre syndrome with a frame-shift mutation in the MSH2 gene: a rare case report and literature review. Int J Gynecol Pathol. 2020;39:136–40.CrossRefPubMed
15.
Zurück zum Zitat Mojtahed A, Schrijver I, Ford JM, Longacre TA, Pai RK. A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mod Pathol. 2011;24:1004–14.CrossRefPubMed Mojtahed A, Schrijver I, Ford JM, Longacre TA, Pai RK. A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mod Pathol. 2011;24:1004–14.CrossRefPubMed
16.
Zurück zum Zitat Vidal CI, Sutton A, Armbrect EA, Lee JB, Litzner BR, Hurley MY, et al. Muir-Torre syndrome appropriate use criteria: effect of patient age on appropriate use scores. J Cutan Pathol. 2019;46:484–9.CrossRefPubMed Vidal CI, Sutton A, Armbrect EA, Lee JB, Litzner BR, Hurley MY, et al. Muir-Torre syndrome appropriate use criteria: effect of patient age on appropriate use scores. J Cutan Pathol. 2019;46:484–9.CrossRefPubMed
17.
Zurück zum Zitat Spielvogel RL, DeVillez RL, Roberts LC. Oral isotretinoin therapy for familial Muir-Torre syndrome. J Am Acad Dermatol. 1985;12:475–80.CrossRefPubMed Spielvogel RL, DeVillez RL, Roberts LC. Oral isotretinoin therapy for familial Muir-Torre syndrome. J Am Acad Dermatol. 1985;12:475–80.CrossRefPubMed
18.
Zurück zum Zitat Ishiguro Y, Homma S, Yoshida T, Ohno Y, Ichikawa N, Kawamura H, et al. Usefulness of PET/CT for early detection of internal malignancies in patients with Muir-Torre syndrome: report of two cases. Surg Case Reps. 2017;3:71.CrossRef Ishiguro Y, Homma S, Yoshida T, Ohno Y, Ichikawa N, Kawamura H, et al. Usefulness of PET/CT for early detection of internal malignancies in patients with Muir-Torre syndrome: report of two cases. Surg Case Reps. 2017;3:71.CrossRef
19.
Zurück zum Zitat Burris CKH, Rodriguez ME, Raven ML, Reddy DN, Xu YG, Wiggs JL, et al. Muir-Torre syndrome: the importance of a detailed family history. Case Rep Ophthalmol. 2019;10:180–5.CrossRefPubMedPubMedCentral Burris CKH, Rodriguez ME, Raven ML, Reddy DN, Xu YG, Wiggs JL, et al. Muir-Torre syndrome: the importance of a detailed family history. Case Rep Ophthalmol. 2019;10:180–5.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Shiki M, Hida T, Sugano K, Kaneko R, Kamiya T, Sakurai A, et al. Muir-Torre syndrome caused by exonic deletion of MLH1 due to homologous recombination. Eur J Dermatol EJD. 2017;27:54–8.CrossRefPubMed Shiki M, Hida T, Sugano K, Kaneko R, Kamiya T, Sakurai A, et al. Muir-Torre syndrome caused by exonic deletion of MLH1 due to homologous recombination. Eur J Dermatol EJD. 2017;27:54–8.CrossRefPubMed
21.
Zurück zum Zitat Banerjee N, Hossain F, Wirtschafter E, Fathizadeh P. Pembrolizumab in the treatment of microsatellite instability-high sebaceous carcinoma: a case report with review of the literature. JCO Precis Oncol. 2020;4:61–5.CrossRefPubMed Banerjee N, Hossain F, Wirtschafter E, Fathizadeh P. Pembrolizumab in the treatment of microsatellite instability-high sebaceous carcinoma: a case report with review of the literature. JCO Precis Oncol. 2020;4:61–5.CrossRefPubMed
22.
Zurück zum Zitat Cino D, Drumm C, Sheahan K, D’Arcy C, Nolan N, Hoti E, et al. Muir-Torre syndrome: a case of unusual coexisting genetic mutations. Clin Exp Dermatol. 2022;47:602–4.CrossRefPubMed Cino D, Drumm C, Sheahan K, D’Arcy C, Nolan N, Hoti E, et al. Muir-Torre syndrome: a case of unusual coexisting genetic mutations. Clin Exp Dermatol. 2022;47:602–4.CrossRefPubMed
23.
Zurück zum Zitat Joshi TP, Farr MA, Lewis DJ. Isotretinoin as chemoprophylaxis for cutaneous malignancies in Muir-Torre syndrome: a novel concept. Dermatol Ther. 2022;35: e15540.CrossRefPubMed Joshi TP, Farr MA, Lewis DJ. Isotretinoin as chemoprophylaxis for cutaneous malignancies in Muir-Torre syndrome: a novel concept. Dermatol Ther. 2022;35: e15540.CrossRefPubMed
24.
Zurück zum Zitat Graefe T, Wollina U, Schulz H, Burgdorf W. Muir-Torre syndrome—treatment with isotretinoin and interferon alpha-2a can prevent tumour development. Dermatology (Basel, Switzerland). 2000;200:331–3.CrossRefPubMed Graefe T, Wollina U, Schulz H, Burgdorf W. Muir-Torre syndrome—treatment with isotretinoin and interferon alpha-2a can prevent tumour development. Dermatology (Basel, Switzerland). 2000;200:331–3.CrossRefPubMed
26.
Zurück zum Zitat Shanks A, Laun J, Holstein A, Varshney S, Messina J, Cruse CW. A rare concurrence of Muir-Torre-associated sebaceous carcinoma in the setting of a lipedematous scalp. Case Rep Plastic Surg hand Surg. 2020;7:124–9.CrossRef Shanks A, Laun J, Holstein A, Varshney S, Messina J, Cruse CW. A rare concurrence of Muir-Torre-associated sebaceous carcinoma in the setting of a lipedematous scalp. Case Rep Plastic Surg hand Surg. 2020;7:124–9.CrossRef
Metadaten
Titel
Muir–Torre Syndrome: A Cutaneous Finding Amidst Broader Malignancies
verfasst von
Rohan R. Shah
Priscilla Allman
Robert A. Schwartz
Publikationsdatum
25.01.2023
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 3/2023
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-023-00757-9

Weitere Artikel der Ausgabe 3/2023

American Journal of Clinical Dermatology 3/2023 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.